LONG-TERM THERAPY OF REFRACTORY HODGKIN’S LYMPHOMA (CLINICAL CASE)

R.I. Kunafina1, O.N. Lipatov1,2, I.V. Asfandiyarova1, A.Kh. Muzafarov1, A.I. Iskhakova1, E.I. Kankumasheva1, E.R. Siraeva1, R.K. Fazlinurov1, N.O. Yuldasheva1

1Republican Clinical Oncology Dispensary, Ufa

2Bashkir State Medical University, Ufa

Kunafina Regina I. ― Head of the Department of antitumor drug therapy №1 of the Republican Clinical Oncology Dispensary

73/1 Oktyabrya Ave., Ufa, 450054, Russian Federation, e-mail: kunafinareg2007@yandex.ru, ORCID ID: 0000-0002-6403-5945

 Abstract. Hodgkin’s lymphoma (LH) is a highly treatable disease. The use of modern therapy makes it possible to achieve complete remission from 80 to 95% of patients with primary LH, while the 5-year survival rate exceeds 80-90%. Nevertheless, 5-30% of LH patients have relapses or a primary refractory course of the disease. Therapy with inhibitors of control response points in the absence of a response to line 2 in the case of a chemoresistant form of Hodgkin’s lymphoma allows for long-term and persistent remission. Immunotherapy allows you to increase the time before switching to a new line of treatment, thereby increasing the overall survival of patients with resistant forms of LH.

The article describes the result of the successful use of nivolumab and pembrolizumab in a patient with a refractory, chemoresistant form of LH who has a long history of treatment (21 years)

Key words: Hodgkin lymphoma, chemotherapy, anti-PD1 therapy.